The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 33 sources its claims cite were checked for support.
Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma
Open accessAbstract
Background Drug resistance and poor clinical outcomes in lung adenocarcinoma (LUAD) necessitate robust biomarkers for personalized therapy. Glycolysis reprogramming is a hallmark of cancer, but its clinical utility remains incompletely defined. Methods We integrated TCGA and GEO transcriptomic data with Weighted gene co−expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression to construct a glycolysis−related prognostic signature. A nomogram combining the risk score with clinicopathological factors was developed. Drug sensitivity was predicted using the pRRophetic algorithm. qRT−PCR and xenograft models using A549 and cisplatin−resistant A549/DDP cells validated the expression of candidate genes. Results Patients stratified by glycolysis-related risk scores exhibited significantly distinct survival outcomes, and the glycolysis-based signature functioned as an independent prognostic factor for overall survival in LUAD. The nomogram demonstrated robust predictive performance and effectively estimated patient sensitivity to three commonly used conventional chemotherapeutic agents. In vitro and in vivo studies using A549 cells and their cisplatin-resistant derivative A549/DDP revealed aberrant expression of VIPR1 , ADRB2 , RXFP1 , PDGFB , WNT3A , and SPRY1 in the resistant cell line and in corresponding xenograft tumor tissues. These findings suggest that glycolytic activity is closely associated with both drug resistance and clinical prognosis in LUAD. Conclusions This study identifies a glycolysis-related gene signature with demonstrable utility for prognostic stratification and therapeutic response prediction in LUAD. The proposed integrative model holds promise for enhancing precision treatment decision-making through optimized risk assessment and rational selection of chemotherapeutic regimens.
Overview
CoChat Summary
TL;DR
This bioinformatics study built a 19-gene glycolysis-related prognostic signature for lung adenocarcinoma (LUAD) and validated it across TCGA and GEO cohorts, showing independent prognostic value and a nomogram with improved discrimination. It also linked the signature to predicted chemosensitivity and experimentally examined six glycolysis-related genes in cisplatin-resistant A549/DDP cells and xenografts.
Key findings
- A glycolysis-related risk score based on 19 prognostic genes stratified patients into high- and low-risk groups with significantly different overall survival in TCGA-LUAD, GSE72094, and GSE14814 (external log-rank P = 0.04244); time-dependent AUCs were 0.765/0.729 at 3/5 years in TCGA, 0.657/0.730 in GSE72094, and 0.608/0.613 in GSE14814.
- The risk score was an independent prognostic factor in multivariate Cox analysis: TCGA-LUAD risk score HR = 3.848 and stage HR = 2.068; across LUAD patients, risk score HR = 6.129 and stage HR = 2.930 (P < 0.01). The nomogram achieved AUC = 0.712, outperforming stage alone (0.587) and risk score alone (0.680).
- pRRophetic predicted significant IC50 differences between risk groups for cisplatin, gemcitabine, and doxorubicin, but not gefitinib; the high-risk subgroup had lower predicted IC50 values for the three significant agents.
- In cisplatin-resistant cells, IC50 values were 137.63 μM for A549/DDP and 73.17 μM for H460/DDP versus 18.51 μM for A549 and 21.36 μM for H460. qRT-PCR showed elevated WNT3A, VIPR1, ADRB2, SPRY1, PDGFB, and RXFP1 in resistant cells, with WNT3A, ADRB2, and SPRY1 significant; in A549/DDP-derived tumors, VIPR1, SPRY1, PDGFB, and RXFP1 were significantly higher.
Methods
- Integrated TCGA-LUAD (n = 456) and GEO datasets GSE72094 (n = 369) and GSE14814 (n = 133), requiring complete survival/clinical information and survival time ≥ 90 days; expression data were log2-transformed, quantile-normalized, and batch-corrected with ComBat.
- Used univariate Cox, LASSO with ten-fold cross-validation (λ_min = 0.01215), WGCNA (pink module, 314 genes, correlation −0.54 with glycolysis, P < 0.05), and multivariate Cox to build a 19-gene risk score; median risk score defined high/low groups; evaluated with Kaplan-Meier, timeROC, nomogram with bootstrap internal validation, DESeq2, GISTIC 2.0, ChAMP, and pRRophetic.
- Validated candidate genes by qRT-PCR in A549, H460, A549/DDP, and H460/DDP cells and in a xenograft model using 4-week-old male BALB/c nude mice (n = 6 per group, repeated twice) inoculated with A549 or A549/DDP cells (4×10^6 cells); no chemotherapy was administered.
Limitations
- Stated: the study relied primarily on retrospective public datasets, which may introduce selection bias; the dataset provided only transcriptomic data, so DNA methylation and CNV could not be directly analyzed for the 19 core prognostic genes; validation in large, well-characterized clinical cohorts and prospective/functional studies is still needed.
- Stated/evident: the in vitro IC50 results contradicted the pRRophetic prediction that high-risk patients have lower IC50 values, and the paper explains this as a possible baseline-sensitivity versus acquired-resistance paradox.
- Evident: the xenograft experiment administered no chemotherapy and found no significant differences in tumor volume, tumor weight, or body weight between A549 and A549/DDP groups; external validation detected only 13 of the 19 prognostic genes; and the figure legend notes that methylation/CNV analyses were genome-wide and did not specifically interrogate the 19-gene signature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
12 Valid · 1 Not valid · 4 Not checked · 71 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, six of the 19 prognostic genes are non-enzymatic regulators that modulate glycolytic flux via receptor signaling or transcriptional control (16–21).”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Results > In vitro and In vivo validation of glycolysis-related prognostic markers
What the sources say
- Could not verifycites [16] Weng, 2024, Sleep deprivation triggers the excessive activation of ovarian primordial follicles via beta2 adrenergic receptor signaling, Adv Sci (Weinh) sourceExperimental — accuracy not yet measured
The Results discuss ovarian cell populations after sleep deprivation, and the Discussion describes ADRB2 signaling and KITL expression; neither addresses glycolytic flux or prognostic genes. Searches for glycolytic flux, non-enzymatic regulators, and prognostic genes found no passage supporting the stated count of six among 19. (LLM, conf=0.76)
- Partly supportedcites [17] Vlashi, 2023, Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders, Genes Dis sourceExperimental — accuracy not yet measured
The “Wnt stimulates glycolysis in osteoblasts” section describes Wnt signaling changing glycolytic-enzyme expression and glucose use; Figure 3 also links receptor signaling to proteins in the glycolytic pathway (page numbers unavailable). The paper does not identify a set of 19 prognostic genes or establish that six of them are non-enzymatic regulators, so it supports only the general mechanism. (LLM, conf=0.84)
- Partly supportedcites [18] Feng, 2025, Platelet-derived growth factor subunit B overexpression promotes lung cancer tumor growth and metastasis: The role of glucose metabolism, Cytojournal sourceExperimental — accuracy not yet measured
The Results section (no page number available) reports that PDGFB overexpression increased glycolysis measures in lung cancer cells and discusses downstream signaling that can shift metabolism toward aerobic glycolysis. This supports PDGFB as an example of a signaling-related regulator, but the paper does not establish that six of 19 prognostic genes are non-enzymatic regulators or address transcriptional control across that group. (LLM, conf=0.84)
- Partly supportedcites [19] Jiang, 2023, Integrated multi-omics analysis for lung adenocarcinoma in Xuanwei, China, Aging (Albany NY) sourceExperimental — accuracy not yet measured
The Results section, “Comparative omics analysis of multiple LUAD datasets” (page not available), identifies six significant prognostic factors. It does not identify a set of 19 prognostic genes or describe the six as non-enzymatic regulators of glycolytic flux through receptor signaling or transcriptional control. (LLM, conf=0.84)
- Partly supportedcites [20] Pan, 2025, ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation, Sci Rep sourceExperimental — accuracy not yet measured
The Results section, “The potential mechanism of ADCY4 in BC” (page unavailable), reports an association between low ADCY4 expression and enrichment of glycolysis-related pathways. It does not show that ADCY4 modulates glycolytic flux, and the Discussion describes ADCY4 as having cyclase catalytic domains rather than as non-enzymatic. The paper also does not establish the citing sentence’s count of six among 19 prognostic genes. (LLM, conf=0.86)
- Partly supportedcites [21] Montico, 2025, Suppression of SPRY1 reduces HIF1alpha-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma, J Exp Clin Cancer Res sourceExperimental — accuracy not yet measured
The Results (page unavailable) show that loss of Spry1 reduced glycolytic capacity and HIF1α-dependent expression of glycolysis-related genes in BRAF-mutant melanoma cells. This supports Spry1 as a regulator of glycolysis, but the paper does not identify a set of 19 prognostic genes or establish that six of them are non-enzymatic regulators. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This apparent paradox is mechanistically plausible: highly glycolytic, rapidly proliferating cells in in vitro monolayer systems exhibit heightened sensitivity to cell-cycle-targeting drugs (13, 14).”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Results > In vitro and In vivo validation of glycolysis-related prognostic markers
What the sources say
- Partly supportedcites [13] Rebolledo, 2025, Modular design of mesoporous silica nanoparticles enables bioimaging, dual chemotherapy, and combinatorial gene silencing in triple-negative breast cancer, ACS Appl Mater Interfaces sourceExperimental — accuracy not yet measured
The Introduction says that several chemotherapies disrupt replication, and the Results and Discussion section on cytotoxic evaluation reports reduced viability in drug-treated MDA-MB-231 cell cultures. The paper does not show that glycolysis or rapid proliferation makes cells in 2D monolayers more sensitive to cell-cycle-targeting drugs; its New Approach Methodologies section says only that 3D models may better predict treatment responses than 2D cultures. No page numbers were provided in our copy. (LLM, conf=0.82)
- Partly supportedcites [14] Crous, 2022, Photodynamic therapy of lung cancer, where are we, Front Pharmacol sourceExperimental — accuracy not yet measured
Section 3 (page unavailable) links glycolysis to the energy demands of rapidly proliferating tumor cells. But the passages on chemotherapy in the Introduction (page unavailable) do not say that such cells are more sensitive to cell-cycle-targeting drugs, particularly in in vitro monolayers. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through literature research, six genes (WNT3A, VIPR1, ADRB2, SPRY1, PDGFB, and RXFP1) related to lung cancer and the regulation of glycolytic metabolic pathways were identified among the 19 genes.”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Results > In vitro and In vivo validation of glycolysis-related prognostic markers
What the sources say
- Could not verifycites [16] Weng, 2024, Sleep deprivation triggers the excessive activation of ovarian primordial follicles via beta2 adrenergic receptor signaling, Adv Sci (Weinh) sourceExperimental — accuracy not yet measured
The Results section on ADRB2 and the Discussion describe ADRB2 signaling in ovarian follicles, not lung cancer or glycolytic metabolism. Searches for the six-gene list and for lung cancer, glycolysis, and 19 genes found no passage identifying the claimed group of genes. (LLM, conf=0.76)
- Partly supportedcites [17] Vlashi, 2023, Wnt signaling: Essential roles in osteoblast differentiation, bone metabolism and therapeutic implications for bone and skeletal disorders, Genes Dis sourceExperimental — accuracy not yet measured
The section “Wnt stimulates glycolysis in osteoblasts” (page unavailable) reports that WNT3A stimulates aerobic glycolysis in osteoblast-related cells. It does not identify the other five genes, describe a selection of six from 19 genes, or establish their connection to lung cancer. (LLM, conf=0.84)
- Partly supportedcites [18] Feng, 2025, Platelet-derived growth factor subunit B overexpression promotes lung cancer tumor growth and metastasis: The role of glucose metabolism, Cytojournal sourceExperimental — accuracy not yet measured
The Results section (‘PDGFB modulates aerobic glycolysis of lung cancer cells’; page unavailable) reports that PDGFB overexpression increased markers of glycolysis in lung cancer cell lines. It does not identify the other five named genes or report selecting six genes from a set of 19. (LLM, conf=0.88)
- Partly supportedcites [19] Jiang, 2023, Integrated multi-omics analysis for lung adenocarcinoma in Xuanwei, China, Aging (Albany NY) sourceExperimental — accuracy not yet measured
The Results section on VIPR1 expression links VIPR1 to lung adenocarcinoma and reports enrichment of metabolism-related pathways in patients with low VIPR1 expression. The paper does not identify the stated six genes among 19 genes or link that group to regulation of glycolytic pathways; its Discussion instead emphasizes oxidative phosphorylation and redox metabolism. Page numbers are unavailable in our copy. (LLM, conf=0.82)
- Partly supportedcites [20] Pan, 2025, ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation, Sci Rep sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that RXFP1 and VIPR1 were among hub genes associated with lung adenocarcinoma. It does not identify the claimed six genes among a set of 19 or link them to regulation of glycolytic metabolic pathways. (LLM, conf=0.82)
- Partly supportedcites [21] Montico, 2025, Suppression of SPRY1 reduces HIF1alpha-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma, J Exp Clin Cancer Res sourceExperimental — accuracy not yet measured
The Results section reports that Spry1 loss reduced expression of glycolysis-related genes in BRAF-mutant cutaneous melanoma, supporting a role for SPRY1 in glycolytic metabolism. The paper does not identify the six named genes among a set of 19 or establish their relationship to lung cancer. No page number was provided for the indexed passages. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the pink module with the highest correlation with glycolysis was obtained (correlation of -0.54, P<0.05).”
- Also stated in: § Identification of glycolysis-related prognostic genes in LUAD · plain
“Module–trait relationship analysis revealed that the pink module exhibited the strongest correlation with glycolysis-related phenotypes (Figure 2B).”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Materials and methods > Bioinformatics and statistical analyses
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Identification of glycolysis-related prognostic genes in LUAD · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 28 gene modules were identified, with module sizes ranging from 47 to 2,493 genes (Figure 2A).”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Results > Identification of glycolysis-related prognostic genes in LUAD
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
48 more claims
Create a free account to see all 88 claims and to verify the 3 references still open.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 24
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Discussion
“the mRNA expression levels of WNT3A, VIPR1, ADRB2, SPRY1, PDGFB, and RXFP1 are significantly higher in drug-resistant NSCLC cell lines compared to non-resistant cell lines”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Results > In vitro and In vivo validation of glycolysis-related prognostic markers
“Among these, WNT3A, ADRB2, and SPRY1 exhibited statistically significant upregulation (Figures 8C, D).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Materials and methods > Bioinformatics and statistical analyses
“the screening criteria were P Value < 10–15 and |log2FC|<0.1”
§ Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma > Results > Multi-omics characterization of high- and low-risk LUAD subgroups
“applying thresholds of P < 1 × 10⁻¹5 and |log2 FC| > 0.1”
Citations
Cites
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534 · cited 1×
“It is well established that malignant cells exhibit a metabolic phenotype characterized by increased glycolysis, even under aerobic conditions (22).”
Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., & Chen, D. (2024) · Cancer Epidemiology · doi:10.1016/j.canep.2024.102693 · Cited by 389
Self-citation100 years of the Warburg effect: A cancer metabolism endeavor
Fendt, S.-M. (2024) · Cell · doi:10.1016/j.cell.2024.06.026 · Cited by 223 · cited 1×
“Accumulating evidence has demonstrated a close association between glycolytic activity and tumor cell proliferation, survival, and disease progression across multiple cancer types (27).”
Glycolysis: A multifaceted metabolic pathway and signaling hub
Kierans, S. J., & Taylor, C. T. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107906 · Cited by 198 · cited 1×
“Even under hypoxic conditions, glycolysis remains the predominant pathway for ATP generation in tumor cells (11).”
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197 · cited 1×
“Signi fi cant interpatient differences exist in molecular characteristics, tumor progression dynamics, and treatment sensitivity, posing major challenges to standardized treatment strategies (6, 7).”
Vlashi, R., Zhang, X., Wu, M., & Chen, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.011 · Cited by 165
Self-citationAltered energy metabolism in cancer: A unique opportunity for therapeutic intervention
Zhang, Y., & Yang, J.-M. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.22958 · Cited by 132 · cited 1×
“Beyond energy production, glycolytic intermediates serve as precursors for macro-molecular biosynthesis, support tumor invasion and metastasis, and contribute to the development of drug resistance (12).”
Zhao, J., Jin, D., Huang, M., Ji, J., Xu, X., Wang, F., Zhou, L., Bao, B., Jiang, F., Xu, W., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1416472 · Cited by 84 · cited 1×
“Glycolysis constitutes a canonical hallmark of cancer metabolism and plays a pivotal role in tumor initiation, progression, and adaptation to microenvironmental stress (9).”
Metadata
- Authors
- Zheng, Q., Liu, Y., Li, T., Zhang, X., Geng, Y., Chen, Z., Zhou, J., Fan, W., Wang, Y., Zhang, L., & Cao, Y.
- Affiliations
- University of Science and Technology of China (CN)
- Anhui Medical University (CN)
- Anhui Institute of Medicine (CN)
- Corresponding author
- Wang, Yong
- Zhang, Lei
- Cao, Yuzhu
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2026-07-15
- Volume
- 16
- Pages
- 1871582-1871582
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC13414110
- OpenAlex
- W7168364447
- Semantic Scholar
- 3be9b7cdcb280bc61cee5c707304e27fe20a7c6f
- Cited by
- 0
- References
- 32
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (52373160)
- Key Technologies Research and Development Program of Anhui Province (201904a07020092, 202304295107020050)
- University Natural Science Research Project of Anhui Province (2208085QH238, 2208085MH252)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, glycolysis, drug resistance, prognostic gene signature, cisplatin resistance, chemotherapy response prediction, nomogram, VIPR1, ADRB2, RXFP1, PDGF-B, Wnt3a, SPRY1, overall survival, cancer metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma. https://app.cochat.ai/papers/10.3389/fonc.2026.1871582
- The paper
- Zheng, Q., Liu, Y., Li, T., Zhang, X., Geng, Y., Chen, Z., Zhou, J., Fan, W., Wang, Y., Zhang, L., & Cao, Y. (2026). Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1871582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.